ZYNE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (10 Oct 2023 @ 16:00):

Stats
Today's Volume	861 742
Average Volume	1.04M
Market Cap	70.12M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.646
ATR14	$0.0400 (3.08%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-10	Jones Kenneth T	Buy	30 000	Common Stock
2023-10-10	Jones Kenneth T	Sell	40 520	Common Stock
2023-10-10	Jones Kenneth T	Sell	75 000	Common Stock
2023-10-10	Jones Kenneth T	Sell	21 250	Stock Option (Right to Buy)
2023-10-10	Stephenson Pamela	Sell	27 954	Common Stock

INSIDER POWER
-52.67
Last 100 transactions
Buy: 1 916 312 \| Sell: 5 402 740

Volume Correlation

Long: 0.26 (neutral)

Short: -0.55 (weak negative)

Signal:(58.623) Neutral

Zynerba Pharmaceuticals Correlation

10 Most Positive Correlations
FULT	0.896
BUSE	0.856
CBSH	0.852
GOODM	0.85
CMCT	0.847
CCNE	0.847
COLB	0.847
FBIZ	0.844
AMTB	0.841
INTZ	0.839

10 Most Negative Correlations
AMRB	-0.841
LMRKN	-0.834
LWAC	-0.817
RAVN	-0.811
SRAC	-0.811
CALT	-0.809
OBT	-0.809
LONE	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Zynerba Pharmaceuticals Correlation - Currency/Commodity

0.46
( neutral )

0.47
( neutral )

0.76
( moderate )

-0.74
( moderate negative )

-0.56
( weak negative )

-0.22
( neutral )

Zynerba Pharmaceuticals Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.820

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.210

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.200

Q4	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.